Post-Market Clinical Follow-Up Plan (PMCFP)
This document is used to plan all post-market clinical follow-up activities for the medical device.
|(your product name)||(version)|
For your orientation, here is guidance documents that may further help you to fill out the template:
- MEDDEV Guidance 2.7/1 Rev. 4 on Clinical Evaluation
- MEDDEV Guidance 2.12/2 Rev. 2 on Post-Market Clinical Follow-Up
The post-market clinical follow-up plan is compiled along with concluding the clinical evaluation and is based on the clinical evaluation report. Following Annex XIV MDR, it specifies the methods used to collect and evaluate clinical data with the aim of:
- confirming the safety and performance of the device throughout its product life cycle,
- identifying previously unknown side-effects and monitoring the identified side-effects and contraindications,
- identifying and analyzing emergent risks on the basis of factual evidence,
- ensuring the continued acceptability of the benefit-risk ratio referred to in sections 1 and 9 of annex I MDR, and
- identifying possible systematic misuse or off-label use of the device, with a view to verifying that the intended purpose is correct.
Product Post-Market Clinical Follow-Up
The clinical evaluation report outlined the following risk-benefit-profile for the product:
Current content in the table really just uses random examples for the Apple watch as a (more or less) figurative medical device.
|Risk ID||Residual Risk||Benefit ID||Product Benefit|
|#R1||Inaccurate blood oxygen measurement||#B1||Increased quality of life through higher awareness for healthy lifestyle|
|#R2||(…)||#B2||Higher likelihood of detecting chronic diseases linked to low blood oxygen|
In this section, translate each risk and benefit ID from your report above into a specific objective that can be measured. Based on MEDDEV 2.12./2 guidance, you hereby want to express a “formal hypothesis”.
Entries are again for Apple watch. Another example: if your product is a software to support diagnosis, one of your aims would be to measure a higher sensitivity / specificity of physicians that use your device. The clinical data you collect will support your claimed product benefits at the end of the PMCF interval.
|Risk / Benefit||PMCF Objective||ID|
|Inaccurate blood oxygen measurement||False-high blood oxygen values||#R1|
|Inaccurate blood oxygen measurement||False-low blood oxygen values||#R2|
|Higher likelihood of detecting chronic diseases linked to low blood oxygen||Higher detection of sleep apnea||#B2|
In this section, describe the methods you will use to collect the data you specified above. Generally: if you claim that your product will somehow improve the patient’s well-being - how will you measure that?
For example: if your product is based on machine learning, you may want to calibrate and evaluate your model on customer-specific data before they use it in their clinical setting. Results from such evaluation will give an idea of your model’s generalizability (your objective).
Other examples are: clinical investigations, analysis of retrospective data, structured user feedback analysis (e.g. surveys), etc.
|PMCF Activity||ID||Responsible Role||Due Date|
|Clinical trial||#R1, B#2, (…)||CMO||(…)|
Template Copyright openregulatory.com. See template license.
Please don’t remove this notice even if you’ve modified contents of this template.